| Trial ID: | L5035 |
| Source ID: | NCT04143802
|
| Associated Drug: |
Ly3437943
|
| Title: |
A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: LY3437943|DRUG: Dulaglutide|DRUG: Placebo
|
| Outcome Measures: |
Primary: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration, A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module, Baseline through Day 106 | Secondary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of LY3437943, PK: AUC of LY3437943, Baseline through study completion (12 weeks)|PK: Maximum Concentration (Cmax) of LY3437943, PK: Cmax of LY3437943, Baseline through study completion (12 weeks)|Change from Baseline in Mean Daily Plasma Glucose (PG), Change from baseline in mean daily PG from 6-point PG profile, Baseline through Day 80
|
| Sponsor/Collaborators: |
Sponsor: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
72
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2019-12-18
|
| Completion Date: |
2020-12-28
|
| Results First Posted: |
|
| Last Update Posted: |
2021-01-20
|
| Locations: |
Anaheim Clinical Trials, LLC, Anaheim, California, 92801, United States|Miami Research Associates, Miami, Florida, 33143, United States|PRA International, Lenexa, Kansas, 66219, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, 78229, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT04143802
|
